EUVIMEDObjevte EUVIMED
Randomisierte kontrollierte StudieOpen access · CC BY-NC-ND 4.0

Clenbuterol induces lean mass and muscle protein accretion, but attenuates cardiorespiratory fitness and desensitizes muscle β 2 ‐adrenergic signalling

Morten Hostrup iD, Lukas Moesgaard iD, Mads Fischer iD, Kate Aiko Wickham, Mads Pleshardt, Andreas Breenfeldt Andersen, Jacob Bejder, Martin Thomassen iD, Jens J Nielsen, Yvette Dehnes, Jens Bangsbo iD, Nikolai B Nordsborg iD and 1 more

The Journal of Physiology · 2025

DOI: 10.1113/jp289023 ↗

At a glance

Randomisierte kontrollierte Studie in The Journal of Physiology, 2025. Written by Morten Hostrup and 12 co-authors. Institution: The August Krogh Section for Human and Molecular Physiology, Department of Nutrition, Exercise and Sports, University of Copenhagen, Copenhagen, Denm…. Major MEDLINE topics: Clenbuterol, Cardiorespiratory Fitness, Muscle Proteins, Muscle, Skeletal. Cited 8 times so far (Crossref); 69 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Anti Doping Danmark (ADD).

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

The β 2 ‐adrenergic agonist clenbuterol is widely abused because of its purported fat‐burning actions, muscle accretion properties and performance enhancing effects, and yet it remains unexplored in randomized controlled trials. In the present study, we subjected 11 healthy men (aged 18–40 years) to two 2 week cycles of oral clenbuterol (80 µg day −1 ) or placebo, separated by a 3 week washout. During each cycle, we assessed body composition, cardiorespiratory fitness, sprint power output, cardiac left ventricular mass and intravascular blood volume. We obtained vastus lateralis muscle biopsies and analysed them for protein content, 3‐hydroxyacyl CoA dehydrogenase (HAD) activity, oxidative phosphorylation complex (OXPHOS) abundance, platelet endothelial cell adhesion molecule (PECAM‐1) abundance and β 2 ‐adrenergic signalling. Compared to placebo, clenbuterol induced a 0.91 kg lean mass gain (95% confidence interval = 0.02–1.81, P < 0.05) but had no effect on fat mass. Clenbuterol reduced maximal oxygen uptake by 7% ( P < 0.001) and exercise capacity by 4% ( P < 0.001) but had no effects on sprint power output, left ventricular mass, intravascular blood volume or haemoglobin mass. Clenbuterol increased muscle protein content ( P < 0.05) and PECAM‐1 abundance ( P < 0.05) but repressed HAD activity ( P < 0.01) and OXPHOS complex V abundance ( P < 0.05). Clenbuterol markedly activated muscle protein kinase A ( P < 0.001) and phosphorylated ribosomal protein S6 (Ser235/236) but this effect declined during the 2 week cycle. Although a 2 week clenbuterol cycle effectively induces lean mass gain and muscle protein accretion, it negatively affects cardiorespiratory fitness, represses muscle oxidative capacity, and induces tolerance in β 2 ‐adrenergic signalling and ribosomal protein S6 phosphorylation. The adverse effects of clenbuterol along with its muscle anabolic actions justify its prohibition in elite sports. image Key points Clenbuterol, a potent β 2 ‐adrenergic agonist, has purported fat‐burning and muscle accretion properties. However, its purported effects, along with its potential adverse effects on cardiorespiratory fitness, remain unexplored in humans. A short 2 week clenbuterol cycle induces lean mass gain and muscle protein accretion in healthy young men. Clenbuterol induces β 2 ‐adrenergic signalling and phosphorylates RpS6 Ser235/236 in skeletal muscle, but this signalling response is attenuated with repeated exposure. Clenbuterol negatively affects cardiorespiratory fitness and represses muscle oxidative capacity. Clenbuterol does not affect left ventricular mass, intravascular blood volume or haemoglobin mass.

Subjects

MeSH terms (MEDLINE)

ClenbuterolCardiorespiratory FitnessMuscle ProteinsMuscle, SkeletalReceptors, Adrenergic, beta-2Adrenergic beta-2 Receptor AgonistsHumansMaleAdultYoung AdultAdolescentSignal TransductionBody Composition

Author keywords

dopingmuscle hypertrophyrepartitioningβ‐adrenergic receptorβ‐agonist

Substances

ClenbuterolMuscle ProteinsReceptors, Adrenergic, beta-2Adrenergic beta-2 Receptor Agonists

Authors and institutions

  • The August Krogh Section for Human and Molecular Physiology, Department of Nutrition, Exercise and Sports, University of Copenhagen, Copenhagen, Denmark.
  • Research Unit for Exercise Biology, Department of Public Health, Aarhus University, Aarhus, Denmark.
  • Norwegian Doping Control Laboratory, Oslo University Hospital, Oslo, Norway.

ORCID profiles: Morten Hostrup, Lukas Moesgaard, Mads Fischer, Martin Thomassen, Jens Bangsbo, Nikolai B Nordsborg

Funding

  • Anti Doping Danmark (ADD)

Cite

APA

Hostrup, M., Moesgaard, L., Fischer, M., Wickham, K. A., Pleshardt, M., Andersen, A. B., Bejder, J., Thomassen, M., Nielsen, J. J., Dehnes, Y., Bangsbo, J., Nordsborg, N. B., & Jessen, S. (2025). Clenbuterol induces lean mass and muscle protein accretion, but attenuates cardiorespiratory fitness and desensitizes muscle β 2 ‐adrenergic signalling. The Journal of Physiology. https://doi.org/10.1113/jp289023

Vancouver

Hostrup M, Moesgaard L, Fischer M, Wickham KA, Pleshardt M, Andersen AB, et al. Clenbuterol induces lean mass and muscle protein accretion, but attenuates cardiorespiratory fitness and desensitizes muscle β 2 ‐adrenergic signalling. The Journal of Physiology. 2025. doi:10.1113/jp289023

BibTeX
@article{Hostrup2025,
  author = {Hostrup, Morten and Moesgaard, Lukas and Fischer, Mads and Wickham, Kate Aiko and Pleshardt, Mads and Andersen, Andreas Breenfeldt and Bejder, Jacob and Thomassen, Martin and Nielsen, Jens J and Dehnes, Yvette and Bangsbo, Jens and Nordsborg, Nikolai B and Jessen, Søren},
  title = {Clenbuterol induces lean mass and muscle protein accretion, but attenuates cardiorespiratory fitness and desensitizes muscle β 2 ‐adrenergic signalling},
  journal = {The Journal of Physiology},
  year = {2025},
  doi = {10.1113/jp289023}
}
Start for free →